CTS Corporation Reports Strong Q2 2026 Performance with Elevated Margins and Strategic Shifts
CTS Corporation reported strong second-quarter results for fiscal year 2026, driven by record gross margins of 41.5%. The company attributed this to a favorable shift toward diversified end markets, which now account for 59% of total revenue. Growth was particularly robust in the medical segment (up 45% YoY) and industrial markets (up 16%), while transportation sales declined slightly due to cautious global light vehicle production impacted by tariffs and geopolitical uncertainties. Management is transitioning from a component supplier model toward delivering high-value integrated subsystems, especially for aerospace and defense. The company raised its full-year revenue guidance to $565-$585 million, citing continued momentum in diversified markets despite challenges in transportation. Aerospace and defense are expected to see stronger performance later in the year as government funding accelerates. Non-recurring factors included a favorable EPS impact of $0.07 from foreign currency benefits and an R&D reimbursement. A major sensor award with a North American OEM underscored CTS's powertrain-agnostic strategy, while management remains cautious about transportation due to ongoing tariff developments.
Topics: financial performance market dynamics segment growth strategic pivot